AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01375361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: 2.5mg Albuterol inhaled on enrollment and at 4 hours in the emergency department.
Study NCT01375361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 2.5mg Normal Saline inhaled on enrollment and at 4 hours in emergency department.
Study NCT03717831 — intervention group
Intervention type: OTHER
Intervention: Observational study of standard of care
Description: Observational cohort study
Study NCT03199937 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flexible Futures
Description: Flexible Futures is a novel and innovative cognitive-behavioral treatment that directly addresses executive function and self-regulation deficits in ASD. Flexible futures targets flexibility and planning through self-regulatory scripts that are consistently modeled and reinforced. Scripts compensate for the inner speech and organization/integration deficits in ASD, and are practiced repeatedly to achieve automaticity. Content focuses on key functions needed for college success, such as: intrinsic motivation, how to implement skills socially, self-advocacy skills application of flexibility and organization scripts and strategies in the service of a long-term goal, and management of time and priorities.
Study NCT03199937 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current standard of care
Description: Flexible Futures will be compared to a social skills treatment as usual that capitalizes on current standard of care provided by local school districts.
Study NCT03753633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speech therapy
Description: Oropharyngeal exercises will be performed under the supervision of a speech therapist.
Study NCT03753633 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Inspiratory and expiratory exercises recruiting diaphragmatic muscles
Study NCT03537950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLC
Description: Single oral dose of PLC.
Study NCT03537950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD
Description: Single oral dose of cannabidiol (CBD) - 600mg.
Study NCT03537950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBDV
Description: Single oral dose of cannabidivarin (CBDV) - 600mg.
Study NCT03844490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CESSATION OF CORD PULSE
Description: In this group the umbilical cord will remain unclamped until the spontanous pulsation stops.~At this time, cord clamping will be made.
Study NCT03844490 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CONTROL
Description: In this group management will be carried out as usual routine (cord clamping from one to three minutes after delivey)
Study NCT01217268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training in person centered care by supervision using video-conference
Description: The investigators will use video-conference for supervising and training of staff members in nursing homes
Study NCT00366704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bifeprunox
Description: .25mg titrate up to 20mg/day (week 1) then 30mg/day (weeks 2-8)
Study NCT00366704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: 4mg, QD, 8 week treatment
Study NCT03197363 — intervention group
Intervention type: OTHER
Intervention: Discovering novel risk factors.
Description: The study protocol includes multiple imaging and functional investigations (including heart, carotid, thyroid, liver ultrasound, fundoscopy, plethysmography, pulse wave velocity, ankle-brachial index, ECG, body composition measured by bioimpedance and dual energy x-ray absorptiometry, anthropometric assessment, rhinometry, hand grip test, oral glucose tolerance test, advance glycation end-products measurement, voice recording. There will be a detailed and verified questionnaires concerning various activities of the subject: physical activity, depression, sino-nasal symptoms, prostate hypertrophy, female urinary tract symptoms, quality of life, smoking and drinking addiction, hirsutism.
Study NCT01759212 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cells implantation
Study NCT00542529 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Imprime PGG TM for Injection
Description: Doses of 2.0 and 4.0 mg/kg intravenous Imprime PGG administered over 1-2 hr for up to 4 consecutive days
Study NCT00504010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arnica Montana
Description: Applied to lower extremity once a day for 3 days
Study NCT00504010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo cream
Description: placebo cream applied to leg daily for 3 days
Study NCT00106522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 10-25mg weekly
Study NCT00106522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: 10-25mg weekly
Study NCT00106522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: iv every 4 weeks
Study NCT00106522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8mg/kg iv every 4 weeks
Study NCT00106522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 4mg/kg iv every 4 weeks
Study NCT01350453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LifeCIT
Description: Participants will be asked to aim to wear the C-MIT for 9 hours a day for 5 days/week, including 4-6 hours of structured activities per day: two 30-60 minute sessions of web-based activities and 3-4 hours practicing everyday activities.
Study NCT01350453 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Participants will receive their usual care from their NHS provider.
Study NCT03602456 — intervention group
Intervention type: OTHER
Intervention: Kentucky HEALTH
Description: KY HEALTH is the modified Medicaid program including key components such as community engagement requirements, premiums and lockouts, redetermination lockouts, and the My Rewards incentive program.
Study NCT04025463 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HHMB
Description: Blended, culturally-congruent, evidence-informed care model to increase patient and clinic participation in CVD risk reduction for patients with HIV
Study NCT01567982 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS, prefrontal cortex and parietal cortex
Description: tDCS is a non invasive brain stimulation methods. We will use two anodes to stimulate prefrontal and/or parietal cortex using 2mA current for 20 minutes.
Study NCT01482663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Skin Clinic
Description: The intervention is founded upon three concurrent elements. Firstly, a SKIN-profile generated by data from a baseline questionnaire (S=Susceptibility, K=Competencies, I=Individual characteristics, N=Necessary precautions).~Secondly, a patient self-management book which includes a patient's log and is offered in both an online and a physical form. Also support to self-management is offered through possible asynchronous communication and networking.~Finally, a counselling consultation with a nurse, trained within dermatology.
Study NCT00185250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)
Description: 2 MIU per application in week 1 and 4 MIU per application in weeks 2 to 24 given subcutaneously every other day
Study NCT00185250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)
Description: 2 MIU per application in week 1, 4 MIU per application in weeks 2 to 3 and 8 MIU per application in weeks 4 to 24 given subcutaneously every other day
Study NCT00185250 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.25 ml in week 1 and 0.50 ml in weeks 2 to 24 given subcutaneously every other day
Study NCT00185250 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.25 ml in week 1, 0.50 ml in weeks 2 to 3 and 1.00 ml in weeks 4 to 24 given subcutaneously every other day
Study NCT04354805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Description: (Oral dose of 50 mg/ day for 3 days then doubled to 100mg/day for further 11 days)
Study NCT02880202 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Massage Therapy
Description: The massage therapy is provided by certified massage therapists and delivered in the home setting. Techniques and duration of massage therapy is customized based on input from the patient and/or caregiver at the start of the session regarding nature and location of discomfort and other symptoms, and based on other factors such as contra-indications/complicating factors, medical issues, and additional diagnoses. The number of massage therapy interventions range from 2-3, 1 week apart, with each session lasting between 20-45 minutes in duration.
Study NCT04702282 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ropivacain concentration measurements
Description: Free and total plasma concentrations of ropivacaine were measured within 24 hours using liquid chromatography - mass spectrometry. A population pharmacokinetic model was built using non-linear mixed effect models
Study NCT01936142 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of RenalGuard
Study NCT01884233 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard care will include usual treatment for HIV and a pamphlet that will be provided to the participants with information about ART adherence and relapse prevention.
Study NCT01884233 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Standard care will include usual treatment for HIV and a pamphlet that will be provided to the participants with information about ART adherence and relapse prevention.
Study NCT01884233 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging CBT (TXT-CBT)
Description: Those assigned to TXT-CBT will be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have initial meeting with a CBT clinician to review the core CBT concepts for promoting ART adherence. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
Study NCT01052688 — intervention group
Intervention type: OTHER
Intervention: Maternal blood draw of 30 to 50ml
Description: Maternal blood draw of 30 to 50mls during pregnancy. Blood may be drawn up to 5 times during the pregnancy between weeks 8 and 36 gestation.
Study NCT02484339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride
Description: Arm A: EBRT and timely sequential start with Radium-223 dichloride 55 kBq/kgbw (6 i.v. injections every 4 weeks) and best supportive care until progression or intolerable toxicity.
Study NCT02484339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional or high dose radiotherapy
Description: Arm B: External beam radiotherapy (EBRT)->->conventional or high dose radiotherapy
Study NCT02484339 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional or high dose radiotherapy
Description: Arm B: External beam radiotherapy (EBRT)->->conventional or high dose radiotherapy
Study NCT01868139 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liquid nitrogen spray cryotherapy with the truFreeze device
Description: Low-pressure liquid nitrogen is sprayed through an upper endoscope on the diseased esophageal tissue to freeze and destroy it. The upper endoscope enables direct visualization of mucosal freeze during spray of the liquid nitrogen onto the mucosa and avoids the need for direct contact with the tissues. The target area is frozen and thawed for several consecutive cycles. The treated tissue becomes necrotic and sloughs, with new, healthy tissue regenerating in its place.
Study NCT04657757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraoral apparatus
Description: Eight platelets with different material composition and surface properties are fastened in a holder (carrier rondell) with 15 mm diameter and inserted into the braces. Braces are to be worn for 28 hours in the oral cavity except for meals and oral hygiene procedures. Platelets then are removed and analyzed. After a first course the braces are to be cleaned in chlorhexidine solution in an ultrasonic bath; followed by a second identical course (Braces to be worn for 28 hours in the oral cavity except for meals and oral hygiene procedures).
Study NCT02423239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexanabinol
Description: Patients will receive dexanabinol given once a week, as a slow intravenous infusion (i.v.) over a 3 hour period
Study NCT02423239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Patients will receive Sorafenib at a dose of 400 mg bid (oral administration)
Study NCT02423239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Patients will receive Nab-paclitaxel at a dose of 125mg/m2 intravenous infusion
Study NCT02423239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Patients will receive Gemcitabine at a dose of 1000mg/m2 intravenous infusion
Study NCT02061098 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate extract-first dose-Group A
Description: Group A will consume 1 daily capsule of pomegranate extract for 3 weeks
Study NCT02061098 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-first dose-Group B
Description: Group B will consume 1 daily capsules of placebo for 3 weeks.
Study NCT02061098 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate extract-first dose-Group B
Description: After 3 weeks of washout, group B will consume 1 daily capsule of pomegranate extract for 3 weeks.
Study NCT02061098 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-first dose-Group A
Description: After 3 weeks of washout, group A will consume 1 daily capsule of placebo for 3 weeks.
Study NCT02061098 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate extract-second dose-Group A
Description: After 3 weeks of washout, group A will consume 4 daily capsules of pomegranate extract for 3 weeks.
Study NCT02061098 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-second dose-Group B
Description: After 3 weeks of washout, group B will consume 4 daily capsules of placebo for 3 weeks.
Study NCT02061098 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate extract-second dose-Group B
Description: After 3 weeks of washout, group B will consume 4 daily capsules of pomegranate extract for 3 weeks.
Study NCT02061098 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-second dose-Group A
Description: After 3 weeks of washout, group A will consume 4 daily capsules of placebo for 3 weeks.
Study NCT02456662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: 8mg PO ondansetron 30 minutes prior to 200mg PO doxycycline
Study NCT02456662 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo (identical to study medication- ondansetron) PO 30 minutes prior to 200mg PO doxycycline
Study NCT02422485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate
Description: Salsalate is a non-acetylated dimer of salicylic acid, and is classified as a NSAID. The chemical name of salsalate is 2-hydroxy-benzoic acid, 2-carboxyphenyl ester. Salsalate has a molecular weight (MW) of 258.226 Da and a molecular formula of C14H10O5.
Study NCT01159379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ertapenem
Description: intravenous, 1 gram, once
Study NCT04547049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: 4 mg/m2/day administered IV day -10 through -9.
Study NCT04547049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: 3.2 mg/kg/day administered IV day -8 through -6.
Study NCT04547049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 1.8 g/m2/day administered IV day -5 through -4.
Study NCT04547049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Me-CCNU
Description: 250mg/m2 once administered orally on day -3.
Study NCT04547049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabbit antithymocyte globulin
Description: 1.5mg/kg/day administered IV day -5 through -2.
Study NCT04547049 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic HSCT
Description: Day 0
Study NCT04547049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin A
Description: 2.5 mg/kg/day administered intravenously from day -7, target: 200-300ng/mL. Usually tapered during the second month, and ended in complete withdrawal during the ninth month after transplantation.
Study NCT04547049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: 500 mg/day administered intravenously from day -9, ended in complete withdrawal on day +100.
Study NCT04547049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX
Description: 15 mg/m2 administered intravenously on day +1, 10mg/m2 on day +3, +6, and +9.
Study NCT03142438 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F&P Seal Improvement Project
Description: Participants will be placed on this arm for a total 14 ± 4 days from Visit 1. Participants will be using the trial full face or nasal mask during this treatment arm.
Study NCT02496910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH22162
Study NCT02496910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan/Amlodipine 80/5 mg (FDC)
Study NCT02496910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone 25mg
Study NCT00919555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone and Tretinoin
Description: Tretinoin: 1 pill twice a day (10 mg/bid) Pioglitazone HCL: 1 pill once a day (30 mg/qd)
Study NCT00919555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin and Pioglitazone HCL
Description: Tretinoin 10 mg 1 pill po twice a day Pioglitazone HCL 30 mg 1 pill po once a day
Study NCT00919555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03318939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poziotinib
Description: The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.~* Cohorts 1-3: 16 mg QD~* Cohort 4: 8 mg BID~* Cohort 5: randomized to 8 mg BID or 6 mg BID or 10 mg QD~* Cohorts 6 and 7: 8 mg BID
Study NCT05408104 — intervention group
Intervention type: DRUG
Intervention: tolvaptan
Description: LVAD recipients with post-operative hyponatremia (Na \< 135 mEq/L). Subjects took tolvaptan 15 mg daily as part of their standard care.
Study NCT04398641 — intervention group
Intervention type: OTHER
Intervention: Evaluation of pre- and postoperative gastrointestinal functional outcomes
Description: Gastrointestinal functional outcomes will be evaluated using the LARS and the GIQLI by Eypasch questionnaires.
Study NCT04569383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-SARS-2-S vaccinations (days 0 & 28)
Description: Vaccination with MVA-SARS-2-S in two escalating dose regimens
Study NCT04569383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comirnaty
Description: Vaccination with Comirnaty (21 day interval)
Study NCT04470609 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule
Description: Two doses of low dosage(50U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
Study NCT04470609 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule
Description: Two doses of medium dosage(100U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
Study NCT04470609 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule
Description: Two doses of high dosage(150U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
Study NCT04470609 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo on a 0- and 28-day schedule
Description: Two doses of placebo at the vaccination schedule of day 0,28
Study NCT03457454 — intervention group
Intervention type: OTHER
Intervention: Primary Care Provider/Staff Participants Interview
Description: -Approximately a 30 minute interview
Study NCT03457454 — intervention group
Intervention type: OTHER
Intervention: Patient Participant Interview
Description: -Approximately 45-60 minute interview
Study NCT03457454 — intervention group
Intervention type: OTHER
Intervention: Patient Participant Anonymous Survey
Description: -Survey completion will take approximately 15 minutes